Discussion on the Selection of ACEI and ARB for the Patients with COVID-19 and Hypertension from ACE2

查看全文 作　　者：Jinfeng [1]CHEN;Zhongyi [1]LEI;Chaofeng [1]LIU;Hong [1]FAN;Peng [2]LEI;Xueping [1]WU;Xiaoyong [1]YU;Yanfen [1]ZHOU;Jiejun [3]HOU

机构地区：[1]Chinese Medical Science Master Research Institute, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an 710003, China;[2]Shaanxi Provincial People's Hospital, Xi'an 710068, China;[3]Shaanxi University of Chinese Medicine, Xianyang 712046, China

出　　处：《Medicinal Plant》索引2020年第11卷第4期,共5页

基　　金：The Third Session of National TCM Master Project of the National Administration of Traditional Chinese Medicine/National Famous TCM Doctor Inheritance Studio Construction Project(GuoZhong YiYaoBanRenJiaoHan2018119)。 摘　　要：With the wide spread of COVID-19,some studies have confirmed that novel coronavirus enters the cell through the binding of spike protein and ACE2 protein,which has the risk of causing the virus to enter the cell to accelerate its transmission.ACEI and ARB are the key drugs for the treatment of hypertension and are widely used in clinic.They are good for ventricular and vascular remodeling in patients with hypertension,coronary heart disease and heart failure.ACEI and ARB drugs may increase the expression of ACE2 in lung tissue and increase the risk of aggravation of the disease.According to the advice of hypertension experts:for mild ordinary COVID-19 patients with hypertension,we can consider discontinuing ACEI and ARB drugs,while for severe COVID-19 patients with hypertension,ACEI and ARB drugs should be stopped immediately.During the discontinuation period,temporary replacement therapy with diuretics,dipine and vasodilatation hypotensive drugs can be considered. 关键词：COVID-19 HYPERTENSION ACE2 ACEI ARB

相关文献

参考文献（36）
引证文献（0）
耦合文献（6447）

参考文献(36)

耦合文献(6447)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Discussion on the Selection of ACEI and ARB for the Patients with COVID-19 and Hypertension from ACE2

参考文献(36)

耦合文献(6447)

用户提示